Aethlon Medical, Inc. reported its financial results for the fiscal fourth quarter and full year ended March 31, 2025, on June 26, 2025. As of March 31, 2025, the company held a cash balance of approximately $5.5 million.
Consolidated operating expenses for fiscal year 2025 were approximately $9.3 million, representing a decrease of $3.3 million, or 26%, compared to $12.6 million for fiscal year 2024. This reduction was driven by lower payroll, professional fees, and general and administrative costs, partially offset by increased clinical trial expenses for the Australian study. The operating loss for the fiscal year decreased to $9.3 million from $12.6 million in the prior year.
The company completed Hemopurifier treatments in the first three participants of its Australian oncology trial, with all patients completing treatment without device deficiencies or immediate complications. Aethlon also received formal approval from India's Central Drugs Standard Control Organization (CDSCO) on June 19, 2025, to initiate a similar trial. Additionally, preclinical data showing 98.5% removal of platelet-derived extracellular vesicles was published, and collaborative research on Long COVID was accepted for presentation at the Keystone Symposium.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.